Edgar Filing: Horizon Technology Finance Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016

		OR

¨		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 814-00802

HORIZON TECHNOLOGY FINANCE CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE		27-2114934
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

312 Farmington Avenue
Farmington, CT		06032
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (860) 676-8654

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨ ..

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨		Accelerated filer þ		Non-accelerated filer ¨		Smaller Reporting Company ¨
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ .

As of May 3, 2016, the Registrant had 11,542,430 shares of common stock, $0.001 par value, outstanding.

HORIZON TECHNOLOGY FINANCE CORPORATION

FORM 10-Q

TABLE OF CONTENTS

		Page
	PART I
Item 1.	Consolidated Financial Statements	3

	Consolidated Statements of Assets and Liabilities as of March 31, 2016 and December 31, 2015 (unaudited)	3
	Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 (unaudited)	4
	Consolidated Statements of Changes in Net Assets for the three months ended March 31, 2016 and 2015 (unaudited)	5
	Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited)	6
	Consolidated Schedules of Investments as of March 31, 2016 and December 31, 2015 (unaudited)	7
	Notes to the Consolidated Financial Statements (unaudited)	19
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	37
Item 3.	Quantitative And Qualitative Disclosures About Market Risk	49
Item 4.	Controls and Procedures	49

	PART II
Item 1.	Legal Proceedings	50
Item 1A.	Risk Factors	50
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	50
Item 3.	Defaults Upon Senior Securities	50
Item 4.	Mine Safety Disclosures	50
Item 5.	Other Information	50
Item 6.	Exhibits	50
	Signatures	51

EX-31.1
EX-31.2
EX-32.1
EX-32.2

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Assets and Liabilities (Unaudited)

(Dollars in thousands, except share and per share data)

	March 31, 2016			December 31, 2015

Assets
Non-affiliate investments at fair value (cost of $251,276 and $255,494, respectively) (Note 4)	$	245,035		$	250,267
Investments in money market funds		291			285
Cash		17,263			20,765
Restricted investments in money market funds		652			1,091
Interest receivable		7,558			6,258
Other assets		2,036			2,230
Total assets	$	272,835		$	280,896

Liabilities
Borrowings (Note 6)	$	109,151		$	114,954
Distributions payable		3,982			3,980
Base management fee payable (Note 3)		425			385
Incentive fee payable (Note 3)		1,099			1,028
Other accrued expenses		958			798
Total liabilities		115,615			121,145

Commitments and Contingencies (Note 7)

Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2016 and December 31, 2015		—			—
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 11,653,972 and 11,648,594 shares issued and 11,540,590 and 11,535,212 shares outstanding as of March 31, 2016 and December 31, 2015, respectively		12			12
Paid-in capital in excess of par		179,761			179,707
Distributions in excess of net investment income		(1,591	)		(2,006	)
Net unrealized depreciation on investments		(6,241	)		(5,227	)
Net realized loss on investments		(14,721	)		(12,735	)
Total net assets		157,220			159,751
Total liabilities and net assets	$	272,835		$	280,896
Net asset value per common share	$	13.62		$	13.85

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(Dollars in thousands, except share and per share data)

	For the Three Months Ended
	March 31,
	2016			2015
Investment income
Interest income on non-affiliate investments	$	9,003		$	6,562
Prepayment fee income on non-affiliate investments		167			520
Fee income on non-affiliate investments		127			184
Total investment income		9,297			7,266
Expenses
Interest expense		1,534			1,587
Base management fee (Note 3)		1,284			1,031
Performance based incentive fee (Note 3)		1,099			736
Administrative fee (Note 3)		281			268
Professional fees		501			431
General and administrative		201			260
Total expenses		4,900			4,313
Net investment income before excise tax		4,397			2,953
Provision for excise tax		—			10
Net investment income		4,397			2,943

Net realized and unrealized (loss) gain on investments
Net realized loss on investments		(1,986	)		(230	)
Net unrealized (depreciation) appreciation on investments		(1,014	)		1,132
Net realized and unrealized (loss) gain on investments		(3,000	)		902
Net increase in net assets resulting from operations	$	1,397		$	3,845
Net investment income per common share	$	0.38		$	0.30
Net increase in net assets per common share	$	0.12		$	0.39
Distributions declared per share	$	0.345		$	0.345
Weighted average shares outstanding		11,538,003			9,807,198

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Changes in Net Assets (Unaudited)

(Dollars in thousands, except share data)

	Common Stock				Paid-In Capital in Excess of			Accumulated Undistributed (Distributions in Excess of) Net Investment			Net Unrealized Depreciation on			Net Realized Loss on			Total Net
	Shares		Amount		Par			Income			Investments			Investments			Assets
Balance at December 31, 2014		9,628,124	$	10	$	155,240		$	(1,102	)	$	(4,737	)	$	(11,163	)	$	138,248
Issuance of common stock, net of offering costs		2,000,000		2		26,667			—			—			—			26,669
Net increase in net assets resulting from operations		—		—		—			2,943			1,132			(230	)		3,845
Issuance of common stock under dividend reinvestment plan		2,493		—		34			—			—			—			34
Distributions declared		—		—		—			(3,783	)		—			—			(3,783	)
Reclassification of permanent tax differences (Note 2)		—		—		(971	)		893			—			78			—
Balance at March 31, 2015		11,630,617	$	12	$	180,970		$	(1,049	)	$	(3,605	)	$	(11,315	)	$	165,013

Balance at December 31, 2015		11,535,212	$	12	$	179,707		$	(2,006	)	$	(5,227	)	$	(12,735	)	$	159,751
Net increase in net assets resulting from operations		—		—		—			4,397			(1,014	)		(1,986	)		1,397
Issuance of common stock under dividend reinvestment plan		5,378		—		54			—			—			—			54
Distributions declared		—		—		—			(3,982	)		—			—			(3,982	)
Balance at March 31, 2016		11,540,590	$	12	$	179,761		$	(1,591	)	$	(6,241	)	$	(14,721	)	$	157,220

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

	For the Three Months Ended
	March 31,
	2016			2015
Cash flows from operating activities:
Net increase in net assets resulting from operations	$	1,397		$	3,845
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:
Amortization of debt issuance costs		153			278
Net realized loss on investments		1,986			230
Net unrealized (depreciation) appreciation on investments		1,014			(1,132	)
Purchase of investments		(16,500	)		(23,933	)
Principal payments received on investments		18,033			25,790
Proceeds from sale of investments		836			—
Changes in assets and liabilities:
Net increase in investments in money market funds		(6	)		(372	)
Net decrease in restricted investments in money market funds		439			555
(Increase) decrease in interest receivable		(243	)		71
Increase in end-of-term payments		(1,075	)		(370	)
Decrease in unearned income		(118	)		(154	)
Decrease in other assets		89			212
Increase in other accrued expenses		160			486
Increase (decrease) in base management fee payable		40			(2	)
Increase (decrease) in incentive fee payable		71			(63	)
Net cash provided by operating activities		6,276			5,441
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs		—			26,667
Repayment of Asset-Backed Notes		(5,850	)		(7,411	)
Distributions paid		(3,928	)		(3,286	)
Net cash (used in) provided by financing activities		(9,778	)		15,970
Net (decrease) increase in cash		(3,502	)		21,411
Cash:
Beginning of period		20,765			8,417
End of period	$	17,263		$	29,828
Supplemental disclosure of cash flow information:
Cash paid for interest	$	1,350		$	1,032
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income	$	81		$	156
Distributions payable	$	3,982		$	3,783
End-of-term payments receivable	$	6,143		$	4,155

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2016

(Dollars in thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount		Investments (6)		Value
Debt Investments — 151.7% (8)
Debt Investments — Life Science — 35.6% (8)
Argos Therapeutics, Inc. (2)(5)	Biotechnology	Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%;	$	5,000	$	4,948	$	4,948
		Ceiling 10.75%), 5.00% ETP, Due 10/1/18)
		Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%;		5,000		4,958		4,958
		Ceiling 10.75%), 5.00% ETP, Due 3/1/19)
New Haven Pharmaceuticals, Inc. (2)	Biotechnology	Term Loan (11.50% cash (Libor + 11.00%; Floor		1,301		1,293		1,293
		11.50%), 11.42% ETP, Due 3/1/19)
		Term Loan (11.50% cash (Libor + 11.00%; Floor		434		431		431
		11.50%), 11.42% ETP, Due 3/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		2,000		1,988		1,988
		10.50%), 6.10% ETP, Due 3/1/19)
		Term Loan (10.00% cash (Libor + 9.50%; Floor		6,265		6,196		6,196
		10.00%), 4.00% ETP, Due 4/1/19)
Palatin Technologies, Inc. (2)(5)	Biotechnology	Term Loan (9.00% cash (Libor + 8.50%; Floor		5,000		4,944		4,944
		9.00%), 5.00% ETP, Due 1/1/19)
		Term Loan (9.00% cash (Libor + 8.50%; Floor		5,000		4,942		4,942
		9.00%), 5.00% ETP, Due 8/1/19)
Sample6, Inc. (2)	Biotechnology	Term Loan (9.50% cash (Libor + 9.00%; Floor		1,555		1,551		1,551
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)
		Term Loan (9.50% cash (Libor + 9.00%; Floor		945		941		941
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)
		Term Loan (9.50% cash (Libor + 9.00%; Floor		2,500		2,483		2,483
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)
IntegenX Inc. (2)	Medical Device	Term Loan (10.75% cash (Libor + 10.25%; Floor		3,750		3,708		3,708
		10.75%; Ceiling 12.75%), 3.50% ETP, Due 7/1/18)
Lantos Technologies, Inc. (2)	Medical Device	Term Loan (11.50% cash (Libor + 11.00%; Floor		3,354		3,313		3,313
		11.50%), 5.00% ETP, Due 2/1/18)
Mederi Therapeutics, Inc. (2)	Medical Device	Term Loan (12.26% cash (Libor + 11.82%), 4.00% ETP,		2,490		2,470		2,463
		Due 7/1/17)
		Term Loan (12.26% cash (Libor + 11.82%), 4.00% ETP,		2,490		2,470		2,463
		Due 7/1/17)
NinePoint Medical, Inc. (2)	Medical Device	Term Loan (9.25% cash (Libor + 8.75%; Floor		5,000		4,948		4,948
		9.25%), 4.50% ETP, Due 3/1/19)
		Term Loan (9.25% cash (Libor + 8.75%; Floor		2,500		2,467		2,467
		9.25%), 4.50% ETP, Due 3/1/19)
Tryton Medical, Inc. (2)	Medical Device	Term Loan (10.41% cash (Prime + 7.16%), 2.50% ETP,		1,875		1,869		1,869
		Due 9/1/16)
Total Debt Investments — Life Science						55,920		55,906
Debt Investments — Technology — 83.1% (8)
Ekahau, Inc. (2)	Communications	Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)		549		548		548
		Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)		183		182		182
mBlox, Inc. (2)	Communications	Term Loan (11.50% cash (Libor + 11.00%; Floor		5,000		4,979		4,979
		11.50%; Ceiling 13.00%), 3.40% ETP, Due 7/1/18)
		Term Loan (11.50% cash (Libor + 11.00%; Floor		5,000		4,979		4,979
		11.50%; Ceiling 13.00%), 3.40% ETP, Due 7/1/18)
		Term Loan (12.00% cash, 100.00% ETP, Due 7/1/16)		1,000		1,000		1,000
		Term Loan (12.00% cash, 100.00% ETP, Due 7/1/16)		500		500		500
Additech, Inc. (2)	Consumer-related Technologies	Term Loan (11.75% cash (Libor + 11.25%; Floor		2,333		2,307		2,307
		11.75%; Ceiling 13.25%), 4.00% ETP, Due 7/1/18)
		Term Loan (11.75% cash (Libor + 11.25%; Floor		2,500		2,467		2,467
		11.75%; Ceiling 13.25%), 4.00% ETP, Due 1/1/19)
Gwynnie Bee, Inc. (2)	Consumer-related Technologies	Term Loan (11.00% cash (Libor + 10.50%; Floor		1,267		1,248		1,248
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 11/1/17)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		733		718		718
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 2/1/18)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		800		788		788
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 4/1/18)
Rhapsody International, Inc. (2)	Consumer-related Technologies	Term Loan (11.00% cash (Libor + 10.50%; Floor		7,500		7,291		7,291
		11.00%), 3.00% ETP, Due 10/1/19)
SavingStar, Inc. (2)	Consumer-related Technologies	Term Loan (10.90% cash (Libor + 10.40%; Floor		3,000		2,947		2,947
		10.90%), 3.00% ETP, Due 6/1/19)
		Term Loan (10.90% cash (Libor + 10.40%; Floor		2,000		1,957		1,957
		10.90%), 3.00% ETP, Due 3/1/20)

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2016

(Dollars in thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount		Investments (6)		Value
The NanoSteel Company, Inc. (2)	Materials	Term Loan (10.00% cash (Libor + 9.50%; Floor		5,000		4,922		4,922
		10.00%), 5.00% ETP, Due 7/1/19)
		Term Loan (10.00% cash (Libor + 9.50%; Floor		2,500		2,461		2,461
		10.00%), 5.00% ETP, Due 7/1/19)
		Term Loan (10.00% cash (Libor + 9.50%; Floor		2,500		2,455		2,455
		10.00%), 5.00% ETP, Due 1/1/20)
Nanocomp Technologies, Inc. (2)	Networking	Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17)		614		607		607
		Term Loan (11.50% cash (Libor + 11.00%; Floor		3,000		2,941		2,941
		11.50%), 3.00% ETP, Due 4/1/20)
Powerhouse Dynamics, Inc. (2)	Power Management	Term Loan (11.20% cash (Libor + 10.70%; Floor		2,500		2,459		2,459
		11.20%), 3.00% ETP, Due 3/1/19)
Avalanche Technology, Inc. (2)	Semiconductors	Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;		1,357		1,353		1,353
		Ceiling 11.75%), 2.40% ETP, Due 4/1/17)
		Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;		1,882		1,876		1,876
		Ceiling 11.75%), 2.40% ETP, Due 10/1/18)
		Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;		2,083		2,042		2,042
		Ceiling 11.75%), 2.00% ETP, Due 2/1/19)
InVisage Technologies, Inc. (2)	Semiconductors	Term Loan (12.00% cash (Libor + 11.50%; Floor		2,125		2,094		2,014
		12.00%; Ceiling 14.00%), 2.00% ETP, Due 4/1/18)
		Term Loan (12.00% cash (Libor + 11.50%; Floor		850		836		805
		12.00%; Ceiling 14.00%), 2.00% ETP, Due 10/1/18)
Luxtera, Inc. (2)	Semiconductors	Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%;		1,404		1,386		1,386
		Ceiling 12.25%), 13.00% ETP, Due 7/1/17)
		Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%;		783		780		780
		Ceiling 12.25%), 13.00% ETP, Due 7/1/17)
		Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%),		833		829		829
		4.50% ETP, Due 12/1/18)
		Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%),		833		828		828
		4.50% ETP, Due 12/1/18)
Xtera Communications, Inc. (2)(5)	Semiconductors	Term Loan (12.50% cash, 15.65% ETP, Due 12/31/16)		3,380		3,353		3,353
		Term Loan (12.50% cash, 21.75% ETP, Due 12/31/16)		939		931		931
Bridge2 Solutions, Inc.	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		4,000		3,970		3,970
		11.50%; Ceiling 14.50%), 2.00% ETP, Due 7/1/19)
		Term Loan (11.50% cash (Libor + 11.00%; Floor		1,000		995		995
		11.50%; Ceiling 14.50%), 2.00% ETP, Due 1/1/20)
Crowdstar, Inc. (2)	Software	Term Loan (10.75% cash (Libor + 10.25%; Floor		1,758		1,735		1,735
		10.75%), 3.00% ETP, Due 9/1/18)
Decisyon, Inc. (2)	Software	Term Loan (12.75% cash (Libor + 12.308%; Floor		1,603		1,599		1,490
		12.50%), 6.50% ETP, Due 10/1/17)
		Term Loan (12.75% cash (Libor + 12.308%; Floor		853		714		665
		12.50%), 6.50% ETP, Due 1/1/18)
Digital Signal Corporation	Software	Term Loan (10.69% cash (Libor + 10.25%; Floor		1,500		1,460		1,425
		10.43%), 5.00% ETP, Due 7/1/19)
		Term Loan (10.69% cash (Libor + 10.25%; Floor		1,500		1,460		1,425
		10.43%), 5.00% ETP, Due 7/1/19)
Education Elements, Inc. (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor		2,000		1,970		1,970
		10.50%), 4.00% ETP, Due 1/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		1,500		1,472		1,472
		10.50%), 4.00% ETP, Due 8/1/19)
Netuitive, Inc. (2)	Software	Term Loan (12.75% cash, Due 7/1/16)		760		759		759
Nomi Corporation	Software	Term Loan (10.59% cash (Libor + 10.15%; Floor		3,750		3,714		3,226
		10.35%), 2.00% ETP, Due 1/1/20)
		Term Loan (10.59% cash (Libor + 10.15%; Floor		3,750		3,714		3,226
		10.35%), 2.00% ETP, Due 1/1/20)
ScoreBig, Inc. (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor		3,500		3,453		3,453
		10.50%), 4.00% ETP, Due 4/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		3,500		3,453		3,453
		10.50%), 4.00% ETP, Due 4/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		2,000		1,944		1,944
		10.50%), 4.00% ETP, Due 3/1/20)
SIGNiX, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		2,800		2,757		2,430
		11.50%), Due 7/1/18)
SilkRoad Technology, Inc. (2)	Software	Term Loan (10.85% cash (Libor + 10.35%; Floor		7,500		7,441		7,441
		10.85%; Ceiling 12.85%), 3.00% ETP, Due 6/1/19)

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2016

(Dollars in thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount		Investments (6)		Value
Skyword, Inc.	Software	Term Loan (11.45% cash (Libor + 10.95%; Floor		4,000		3,928		3,928
		11.45%), 3.00% ETP, Due 8/1/19)
Social Intelligence Corp. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor		565		552		541
		11.00%; Ceiling 13.00%), 3.50% ETP, Due 12/1/17)
SpringCM, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		4,125		4,082		4,082
		11.50%; Ceiling 13.00%), 2.00% ETP, Due 1/1/18)
Sys-Tech Solutions, Inc. (2)	Software	Term Loan (11.65% cash (Libor + 11.15%; Floor		4,600		4,572		4,572
		11.65%; Ceiling 12.65%), 4.50% ETP, Due 3/1/18)
		Term Loan (11.65% cash (Libor + 11.15%; Floor		4,167		4,137		4,137
		11.65%; Ceiling 12.65%), 9.00% ETP, Due 5/1/18)
VBrick Systems, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		1,600		1,589		1,589
		11.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17)
Vidsys, Inc. (2)	Software	Term Loan (13.00% cash, 7.58% ETP, Due 12/1/17)		2,810		2,810		2,810
xTech Holdings, Inc. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor		2,000		1,972		1,972
		11.00%), 3.00% ETP, Due 4/1/19)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		2,000		1,963		1,963
		11.00%), 3.00% ETP, Due 3/1/20)
Total Debt Investments — Technology						132,279		130,626
Debt Investments — Cleantech — 6.8% (8)
Renmatix, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, Due 10/1/16)		1,182		1,180		1,180
Semprius, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 5.00% ETP, Due 6/1/16)		435		422		422
Rypos, Inc. (2)	Energy Efficiency	Term Loan (11.99% cash, 4.25% ETP, Due 6/1/17)		2,250		2,229		2,229
		Term Loan (11.99% cash, 4.25% ETP, Due 1/1/18)		897		885		885
Lehigh Technologies, Inc. (2)	Waste Recycling	Term Loan (10.16% cash (Libor + 9.72%), 6.75% ETP,		3,000		2,963		2,963
		Due 8/1/19)
		Term Loan (10.16% cash (Libor + 9.72%), 6.75% ETP,		3,000		2,977		2,977
		Due 8/1/19)
Total Debt Investments — Cleantech						10,656		10,656
Debt Investments — Healthcare information and services — 26.2% (8)
Interleukin Genetics, Inc. (2)(5)	Diagnostics	Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%)		5,000		4,892		4,892
		4.50% ETP, Due 10/1/18)
LifePrint Group, Inc. (2)	Diagnostics	Term Loan (11.00% cash (Libor + 10.50%; Floor		2,100		2,070		2,070
		11.00%; Ceiling 12.50%), 3.00% ETP, Due 1/1/18)
Watermark Medical, Inc. (2)	Other Healthcare	Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;		3,500		3,494		3,494
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
		Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;		3,500		3,494		3,494
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
		Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;		1,250		1,248		1,248
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
Innovatient Solutions, Inc. (2)(11)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor		972		949		250
		11.00%, Ceiling 13.00%); 4.00% ETP, Due 7/1/18)
MedAvante, Inc. (2)	Software	Term Loan (9.75% cash (Libor + 9.25%; Floor		3,000		2,961		2,961
		9.75%), 4.00% ETP, Due 1/1/19)
		Term Loan (9.75% cash (Libor + 9.25%; Floor		3,000		2,961		2,961
		9.75%), 4.00% ETP, Due 1/1/19)
		Term Loan (9.75% cash (Libor + 9.25%; Floor		4,000		3,938		3,938
		9.75%), 4.00% ETP, Due 7/1/19)
Medsphere Systems Corporation (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor		5,000		4,927		4,927
		10.50%), 7.00% ETP, Due 7/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		2,500		2,463		2,463
		10.50%), 7.00% ETP, Due 7/1/19)
Recondo Technology, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		1,211		1,207		1,207
		11.50%), 6.60% ETP, Due 12/1/17)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		2,188		2,182		2,182
		11.00%), 4.50% ETP, Due 12/1/17)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		2,188		2,183		2,183
		10.50%), 2.75% ETP, Due 12/1/17)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		3,000		2,968		2,968
		10.50%), 2.50% ETP, Due 1/1/19)
Total Debt Investments — Healthcare information and services						41,937		41,238
Total Debt Investments						240,792		238,426

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2016

(Dollars in thousands)

Cost of

Fair

Portfolio Company (1)

Sector

Type of Investment (3)(4)(7)(9)(10)

Investments (6)

Value

Warrant Investments — 3.3% (8)

Warrants — Life Science — 0.4% (8)

ACT Biotech Corporation

Biotechnology

1,521,820 Preferred Stock Warrants

—

Argos Therapeutics, Inc. (2)(5)

Biotechnology

33,112 Common Stock Warrants

Celsion Corporation (5)

Biotechnology

5,708 Common Stock Warrants

—

Inotek Pharmaceuticals Corporation (5)

Biotechnology

28,204 Common Stock Warrants

New Haven Pharmaceuticals, Inc. (2)

Biotechnology

103,982 Preferred Stock Warrants

173

Nivalis Therapeutics, Inc. (5)

Biotechnology

18,534 Common Stock Warrants

122

—

Ocera Therapeutics, Inc. (2)(5)

Biotechnology

6,491 Common Stock Warrants

—

Palatin Technologies, Inc. (2)(5)

Biotechnology

608,058 Common Stock Warrants

Revance Therapeutics, Inc. (5)

Biotechnology

34,377 Common Stock Warrants

133

Sample6, Inc. (2)

Biotechnology

351,018 Preferred Stock Warrants

Sunesis Pharmaceuticals, Inc. (5)

Biotechnology

12,302 Common Stock Warrants

—

AccuVein Inc. (2)

Medical Device

75,769 Preferred Stock Warrants

Direct Flow Medical, Inc.

Medical Device

176,922 Preferred Stock Warrants

144

—

EnteroMedics, Inc. (5)

Medical Device

9,402 Common Stock Warrants

347

—

IntegenX, Inc. (2)

Medical Device

158,006 Preferred Stock Warrants

Lantos Technologies, Inc. (2)

Medical Device

1,287,817 Preferred Stock Warrants

Mederi Therapeutics, Inc. (2)

Medical Device

248,736 Preferred Stock Warrants

Mitralign, Inc. (2)

Medical Device

641,909 Preferred Stock Warrants

NinePoint Medical, Inc. (2)

Medical Device

566,038 Preferred Stock Warrants

OraMetrix, Inc. (2)

Medical Device

812,348 Preferred Stock Warrants

—

Tryton Medical, Inc. (2)

Medical Device

122,362 Preferred Stock Warrants

ViOptix, Inc.

Medical Device

375,763 Preferred Stock Warrants

—

Total Warrants — Life Science

1,336

599

Warrants — Technology — 2.2% (8)

Ekahau, Inc. (2)

Communications

978,261 Preferred Stock Warrants

OpenPeak, Inc.

Communications

18,997 Common Stock Warrants

—

Additech, Inc. (2)

Consumer-related Technologies

150,000 Preferred Stock Warrants

Everyday Health, Inc. (5)

Consumer-related Technologies

43,783 Common Stock Warrants

Gwynnie Bee, Inc. (2)

Consumer-related Technologies

268,591 Preferred Stock Warrants

629

If(we), Inc.

Consumer-related Technologies

190,868 Preferred Stock Warrants

Rhapsody International Inc. (2)

Consumer-related Technologies

852,273 Common Stock Warrants

164

158

SavingStar, Inc. (2)

Consumer-related Technologies

98,860 Preferred Stock Warrants

XIOtech, Inc.

Data Storage

2,217,979 Preferred Stock Warrants

SimpleTuition, Inc.

Internet and media

189,573 Preferred Stock Warrants

The NanoSteel Company, Inc. (2)

Materials

147,424 Preferred Stock Warrants

IntelePeer, Inc.

Networking

141,549 Common Stock Warrants

Nanocomp Technologies, Inc. (2)

Networking

681,819 Preferred Stock Warrants

Aquion Energy, Inc.

Power Management

115,051 Preferred Stock Warrants

Powerhouse Dynamics, Inc. (2)

Power Management

290,698 Preferred Stock Warrants

Avalanche Technology, Inc. (2)

Semiconductors

202,602 Preferred Stock Warrants

101

eASIC Corporation (2)

Semiconductors

40,445 Preferred Stock Warrants

InVisage Technologies, Inc. (2)

Semiconductors

185,790 Preferred Stock Warrants

Kaminario, Inc.

Semiconductors

1,087,203 Preferred Stock Warrants

Luxtera, Inc.(2)

Semiconductors

2,304,667 Preferred Stock Warrants

100

Soraa, Inc. (2)

Semiconductors

180,000 Preferred Stock Warrants

Xtera Communications, Inc. (5)

Semiconductors

37,831 Common Stock Warrants

205

—

Bolt Solutions Inc. (2)

Software

202,892 Preferred Stock Warrants

113

112

Bridge2 Solutions, Inc.

Software

75,458 Common Stock Warrants

326

Clarabridge, Inc.

Software

53,486 Preferred Stock Warrants

Crowdstar, Inc. (2)

Software

75,428 Preferred Stock Warrants

Decisyon, Inc. (2)

Software

82,967 Common Stock Warrants

—

Digital Signal Corporation

Software

85,308 Common Stock Warrants

Education Elements, Inc. (2)

Software

238,122 Preferred Stock Warrants

Lotame Solutions, Inc. (2)

Software

288,115 Preferred Stock Warrants

268

Netuitive, Inc.

Software

41,569 Common Stock Warrants

—

Nomi Corporation

Software

2,535,864 Preferred Stock Warrants

—

Riv Data Corp. (2)

Software

237,361 Preferred Stock Warrants

ScoreBig, Inc. (2)

Software

767,626 Preferred Stock Warrants

SIGNiX, Inc. (2)

Software

63,365 Preferred Stock Warrants

Skyword, Inc.

Software

301,056 Preferred Stock Warrants

SpringCM, Inc. (2)

Software

2,385,686 Preferred Stock Warrants

119

Sys-Tech Solutions, Inc.

Software

375,000 Preferred Stock Warrants

242

539

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2016

(Dollars in thousands)

			Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Investments (6)		Value
Vidsys, Inc.	Software	85,399 Preferred Stock Warrants		23		21
Visage Mobile, Inc.	Software	1,692,047 Preferred Stock Warrants		19		—
xTech Holdings, Inc. (2)	Software	158,730 Preferred Stock Warrants		43		43
Total Warrants — Technology				2,321		3,414
Warrants — Cleantech — 0.2% (8)
Renmatix, Inc.	Alternative Energy	53,022 Preferred Stock Warrants		68		64
Semprius, Inc.	Alternative Energy	519,981 Preferred Stock Warrants		25		20
Rypos, Inc. (2)	Energy Efficiency	5,627 Preferred Stock Warrants		44		31
Tigo Energy, Inc. (2)	Energy Efficiency	804,604 Preferred Stock Warrants		100		109
Lehigh Technologies, Inc. (2)	Waste Recycling	272,727 Preferred Stock Warrants		32		33
Total Warrants — Cleantech				269		257
Warrants — Healthcare information and services — 0.5% (8)
Accumetrics, Inc.	Diagnostics	100,928 Preferred Stock Warrants		107		63
BioScale, Inc. (2)	Diagnostics	3,156 Common Stock Warrants		54		—
Candescent Health, Inc. (2)	Diagnostics	519,991 Preferred Stock Warrants		378		—
Helomics Corporation	Diagnostics	13,461 Common Stock Warrants		73		—
Interleukin Genetics, Inc. (2)(5)	Diagnostics	2,492,523 Common Stock Warrants		112		50
LifePrint Group, Inc. (2)	Diagnostics	49,000 Preferred Stock Warrants		29		23
Singulex, Inc.	Other Healthcare	293,632 Preferred Stock Warrants		44		165
Verity Solutions Group, Inc.	Other Healthcare	300,360 Preferred Stock Warrants		100		36
Watermark Medical, Inc. (2)	Other Healthcare	27,373 Preferred Stock Warrants		74		62
Innovatient Solutions, Inc. (2)	Software	157,895 Preferred Stock Warrants		35		—
MedAvante, Inc. (2)	Software	114,285 Preferred Stock Warrants		66		65
Medsphere Systems Corporation (2)	Software	7,097,791 Preferred Stock Warrants		60		204
Recondo Technology, Inc. (2)	Software	556,796 Preferred Stock Warrants		95		194
Total Warrants — Healthcare information and services				1,227		862
Total Warrants				5,153		5,132

Other Investments — 0.4% (8)
ZetrOZ, Inc.	Medical Device	Royalty Agreement		383		400
Vette Technology, LLC	Data Storage	Royalty Agreement Due 4/18/2019		4,399		300
Total Other Investments				4,782		700
Equity — 0.5% (8)
Insmed Incorporated (5)	Biotechnology	33,208 Common Stock		238		421
Revance Therapeutics, Inc.(5)	Biotechnology	4,861 Common Stock		73		85
Sunesis Pharmaceuticals, Inc. (5)	Biotechnology	78,493 Common Stock		83		42
SnagAJob.com, Inc.	Consumer-related Technologies	82,974 Common Stock		9		83
Decisyon, Inc.	Software	3,324,444 Common Stock		146		146
Total Equity				549		777
Total Portfolio Investment Assets — 155.9% (8)			$	251,276	$	245,035

Short Term Investments — Money Market Funds — 0.2% (8)
US Bank Money Market Deposit Account			$	291	$	291
Total Short Term Investments — Money Market Funds			$	291	$	291
Short Term Investments — Restricted Investments— 0.7% (8)
US Bank Money Market Deposit Account (2)			$	652	$	652
Total Short Term Investments — Restricted Investments			$	652	$	652

(1)		All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(2)		Has been pledged as collateral under the Key Facility or the 2013-1 Securitization.

(3)		All investments are less than 5% ownership of the class and ownership of the portfolio company.

(4)		All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”) and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the debt investment, unless otherwise indicated. Debt investments based on LIBOR are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of March 31, 2016 is provided.

(5)		Portfolio company is a public company.

(6)		For debt investments, represents principal balance less unearned income.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

March 31, 2016

(Dollars in thousands)

(7)		Warrants, Equity and Other Investments are non-income producing.

(8)		Value as a percent of net assets.

(9)		The Company did not have any non-qualifying assets under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”), as of March 31, 2016. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10)		ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11)		Debt investment is on non-accrual status at March 31, 2016.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

(Dollars in thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount		Investments (6)		Value
Debt Investments — 151.6 % (8)
Debt Investments — Life Science — 36.6% (8)
Argos Therapeutics, Inc. (2)(5)	Biotechnology	Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%;	$	5,000	$	4,944	$	4,944
		Ceiling 10.75%), 5.00% ETP, Due 10/1/18)
		Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%;		5,000		4,954		4,954
		Ceiling 10.75%), 5.00% ETP, Due 3/1/19)
New Haven Pharmaceuticals, Inc. (2)	Biotechnology	Term Loan (11.50% cash (Libor + 11.00%; Floor		1,301		1,293		1,293
		11.50%), 11.42% ETP, Due 3/1/19)
		Term Loan (11.50% cash (Libor + 11.00%; Floor		434		431		431
		11.50%), 11.42% ETP, Due 3/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		2,000		1,987		1,987
		10.50%), 6.10% ETP, Due 3/1/19)
		Term Loan (10.00% cash (Libor + 9.50%; Floor		6,265		6,190		6,190
		10.00%), 4.00% ETP, Due 4/1/19)
Palatin Technologies, Inc. (2)(5)	Biotechnology	Term Loan (9.00% cash (Libor + 8.50%; Floor		5,000		4,939		4,939
		9.00%), 5.00% ETP, Due 1/1/19)
		Term Loan (9.00% cash (Libor + 8.50%; Floor		5,000		4,937		4,937
		9.00%), 5.00% ETP, Due 8/1/19)
Sample6, Inc. (2)	Biotechnology	Term Loan (9.50% cash (Libor + 9.00%; Floor		1,555		1,550		1,550
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)
		Term Loan (9.50% cash (Libor + 9.00%; Floor		945		940		940
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)
		Term Loan (9.50% cash (Libor + 9.00%; Floor		2,500		2,481		2,481
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)
Sunesis Pharmaceuticals, Inc. (2)(5)	Biotechnology	Term Loan (8.95% cash, 4.65% ETP, Due 10/1/16)		545		544		544
		Term Loan (9.00% cash, 4.65% ETP, Due 10/1/16)		818		815		815
IntegenX Inc. (2)	Medical Device	Term Loan (10.75% cash (Libor + 10.25%; Floor		3,750		3,703		3,703
		10.75%; Ceiling 12.75%), 3.50% ETP, Due 7/1/18)
Lantos Technologies, Inc. (2)	Medical Device	Term Loan (11.50% cash (Libor + 10.50%; Floor		3,500		3,454		3,333
		11.50%), 5.00% ETP, Due 2/1/18)
Mederi Therapeutics, Inc. (2)	Medical Device	Term Loan (12.06% cash (Libor + 11.82%), 4.00% ETP,		2,850		2,826		2,738
		Due 7/1/17)
		Term Loan (12.06% cash (Libor + 11.82%), 4.00% ETP,		2,850		2,826		2,738
		Due 7/1/17)
NinePoint Medical, Inc. (2)	Medical Device	Term Loan (9.25% cash (Libor + 8.75%; Floor		5,000		4,943		4,943
		9.25%), 4.50% ETP, Due 3/1/19)
		Term Loan (9.25% cash (Libor + 8.75%; Floor		2,500		2,464		2,464
		9.25%), 4.50% ETP, Due 3/1/19)
Tryton Medical, Inc. (2)	Medical Device	Term Loan (10.41% cash (Prime + 7.16%), 2.50% ETP,		2,063		2,053		2,053
		Due 9/1/16)
ZetrOZ, Inc. (2)(11)	Medical Device	Term Loan (11.00% cash (Libor + 10.50%; Floor		1,350		1,330		250
		11.00%; Ceiling 12.50%), 3.00% ETP, Due 4/1/18)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		1,350		1,326		250
		11.00%; Ceiling 12.50%), 3.00% ETP, Due 4/1/18)
Total Debt Investments — Life Science						60,930		58,477
Debt Investments — Technology — 80.5% (8)
Ekahau, Inc. (2)	Communications	Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)		704		700		700
		Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)		235		233		233
mBlox, Inc. (2)	Communications	Term Loan (11.50% cash (Libor + 11.00%; Floor		5,000		4,977		4,977
		11.50%; Ceiling 13.00%), 3.40% ETP, Due 7/1/18)
		Term Loan (11.50% cash (Libor + 11.00%; Floor		5,000		4,977		4,977
		11.50%; Ceiling 13.00%), 3.40% ETP, Due 7/1/18)
		Term Loan (12.00% cash, 100.00% ETP, Due 7/1/16)		1,000		1,000		1,000
		Term Loan (12.00% cash, 100.00% ETP, Due 7/1/16)		500		500		500
Overture Networks, Inc. (2)	Communications	Term Loan (10.75% cash, (Libor + 10.25%; Floor		4,104		4,089		4,089
		10.75%), 5.75% ETP, Due 12/1/17)
		Term Loan (10.75% cash (Libor + 10.25%; Floor		2,052		2,043		2,043
		10.75%), 5.75% ETP, Due 12/1/17)
		Term Loan (10.75% cash (Libor + 10.25%; Floor		1,000		992		992
		10.75%), 5.00% ETP, Due 11/1/18)
Additech, Inc. (2)	Consumer-related Technologies	Term Loan (11.75% cash (Libor + 11.25%; Floor		2,500		2,470		2,470
		11.75%; Ceiling 13.25%), 4.00% ETP, Due 7/1/18)

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

(Dollars in thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount		Investments (6)		Value
		Term Loan (11.75% cash (Libor + 11.25%; Floor		2,500		2,464		2,464
		11.75%; Ceiling 13.25%), 4.00% ETP, Due 1/1/19)
Gwynnie Bee, Inc. (2)	Consumer-related Technologies	Term Loan (11.00% cash (Libor + 10.50%; Floor		1,467		1,445		1,445
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 11/1/17)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		833		816		816
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 2/1/18)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		900		886		886
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 4/1/18)
Rhapsody International, Inc. (2)	Consumer-related Technologies	Term Loan (11.00% cash (Libor + 10.50%; Floor		7,500		7,276		7,276
		11.00%), 3.00% ETP, Due 10/1/19)
SavingStar, Inc. (2)	Consumer-related Technologies	Term Loan (10.90% cash (Libor + 10.40%; Floor		3,000		2,911		2,911
		10.90%), 3.00% ETP, Due 6/1/19)
The NanoSteel Company, Inc. (2)	Materials	Term Loan (10.00% cash (Libor + 9.50%; Floor		5,000		4,915		4,915
		10.00%), 5.00% ETP, Due 7/1/19)
		Term Loan (10.00% cash (Libor + 9.50%; Floor		2,500		2,458		2,458
		10.00%), 5.00% ETP, Due 7/1/19)
		Term Loan (10.00% cash (Libor + 9.50%; Floor		2,500		2,452		2,452
		10.00%), 5.00% ETP, Due 1/1/20)
Nanocomp Technologies, Inc. (2)	Networking	Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17)		701		693		693
Powerhouse Dynamics, Inc. (2)	Power Management	Term Loan (11.20% cash (Libor + 10.70%; Floor		2,500		2,456		2,456
		11.20%), 3.00% ETP, Due 3/1/19)
Avalanche Technology, Inc. (2)	Semiconductors	Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;		1,565		1,561		1,561
		Ceiling 11.75%), 2.40% ETP, Due 4/1/17)
		Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;		2,003		1,997		1,997
		Ceiling 11.75%), 2.40% ETP, Due 10/1/18)
		Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;		2,202		2,157		2,157
		Ceiling 11.75%), 2.00% ETP, Due 2/1/19)
InVisage Technologies, Inc. (2)	Semiconductors	Term Loan (12.00% cash (Libor + 11.50%; Floor		2,380		2,345		2,242
		12.00%; Ceiling 14.00%), 2.00% ETP, Due 4/1/18)
		Term Loan (12.00% cash (Libor + 11.50%; Floor		850		835		798
		12.00%; Ceiling 14.00%), 2.00% ETP, Due 10/1/18)
Luxtera, Inc. (2)	Semiconductors	Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%;		1,646		1,645		1,645
		Ceiling 12.25%), 13.00% ETP, Due 7/1/17)
		Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%;		951		926		926
		Ceiling 12.25%), 13.00% ETP, Due 7/1/17)
		Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%),		833		828		828
		4.50% ETP, Due 12/1/18)
		Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%),		833		827		827
		4.50% ETP, Due 12/1/18)
Xtera Communications, Inc. (2)(5)	Semiconductors	Term Loan (12.50% cash, 15.65% ETP, Due 12/31/16)		4,157		4,114		4,114
		Term Loan (12.50% cash, 21.75% ETP, Due 12/31/16)		1,155		1,142		1,142
Bridge2 Solutions, Inc.	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		4,000		3,966		3,966
		11.50%; Ceiling 14.50%), 2.00% ETP, Due 7/1/19)
		Term Loan (11.50% cash (Libor + 11.00%; Floor		1,000		995		995
		11.50%; Ceiling 14.50%), 2.00% ETP, Due 1/1/20)
Crowdstar, Inc. (2)	Software	Term Loan (10.75% cash (Libor + 10.25%; Floor		1,939		1,915		1,915
		10.75%), 3.00% ETP, Due 9/1/18)
Decisyon, Inc. (2)	Software	Term Loan (12.69% cash (Libor + 12.308%; Floor		1,603		1,599		1,514
		12.50%), 6.50% ETP, Due 10/1/17)
		Term Loan (12.69% cash (Libor + 12.308%; Floor		853		847		802
		12.50%), 6.50% ETP, Due 1/1/18)
Digital Signal Corporation	Software	Term Loan (10.54% cash (Libor + 10.25%; Floor		1,500		1,421		1,421
		10.43%), 5.00% ETP, Due 7/1/19)
		Term Loan (10.54% cash (Libor + 10.25%; Floor		1,500		1,457		1,457
		10.43%), 5.00% ETP, Due 7/1/19)
Education Elements, Inc. (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor		2,000		1,967		1,967
		10.50%), 4.00% ETP, Due 1/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		1,500		1,470		1,470
		10.50%), 4.00% ETP, Due 8/1/19)
Netuitive, Inc. (2)	Software	Term Loan (12.75% cash, Due 7/1/16)		1,000		998		998
ScoreBig, Inc. (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor		3,500		3,449		3,449
		10.50%), 4.00% ETP, Due 4/1/19)

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

(Dollars in thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount		Investments (6)		Value
		Term Loan (10.50% cash (Libor + 10.00%; Floor		3,500		3,449		3,449
		10.50%), 4.00% ETP, Due 4/1/19)
SIGNiX, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		3,000		2,953		2,953
		11.50%), Due 7/1/18)
SilkRoad Technology, Inc. (2)	Software	Term Loan (10.85% cash (Libor + 10.35%; Floor		7,500		7,436		7,436
		10.85%; Ceiling 12.85%), 3.00% ETP, Due 6/1/19)
Skyword, Inc.	Software	Term Loan (11.45% cash (Libor + 10.95%; Floor		4,000		3,900		3,900
		11.45%), 3.00% ETP, Due 8/1/19)
Social Intelligence Corp. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor		1,091		1,076		1,067
		11.00%; Ceiling 13.00%), 3.50% ETP, Due 12/1/17)
SpringCM, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		4,500		4,450		4,450
		11.50%; Ceiling 13.00%), 2.00% ETP, Due 1/1/18)
Sys-Tech Solutions, Inc. (2)	Software	Term Loan (11.65% cash (Libor + 11.15%; Floor		5,200		5,168		5,168
		11.65%; Ceiling 12.65%), 4.50% ETP, Due 3/1/18)
		Term Loan (11.65% cash (Libor + 11.15%; Floor		4,667		4,633		4,633
		11.65%; Ceiling 12.65%), 9.00% ETP, Due 5/1/18)
VBrick Systems, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		1,900		1,887		1,887
		11.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17)
Vidsys, Inc. (2)	Software	Term Loan (13.00% cash, 7.58% ETP, Due 12/1/17)		2,810		2,810		2,810
xTech Holdings, Inc. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor		2,000		1,957		1,957
		11.00%), 3.00% ETP, Due 4/1/19)
Total Debt Investments — Technology						128,933		128,654
Debt Investments — Cleantech — 7.5% (8)
Renmatix, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)		173		173		173
		Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)		173		173		173
		Term Loan (10.25% cash, Due 10/1/16)		1,667		1,663		1,663
Semprius, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 5.00% ETP, Due 6/1/16)		860		840		840
Rypos, Inc. (2)	Energy Efficiency	Term Loan (11.80% cash, 4.25% ETP, Due 6/1/17)		2,430		2,314		2,314
		Term Loan (11.80% cash, 4.25% ETP, Due 1/1/18)		947		913		913
Lehigh Technologies, Inc. (2)	Waste Recycling	Term Loan (9.96% cash (Libor + 9.72%), 6.75% ETP,		3,000		2,961		2,961
		Due 8/1/19)
		Term Loan (9.96% cash (Libor + 9.72%), 6.75% ETP,		3,000		2,975		2,975
		Due 8/1/19)
Total Debt Investments — Cleantech						12,012		12,012
Debt Investments — Healthcare information and services — 27.0% (8)
Interleukin Genetics, Inc. (2)(5)	Diagnostics	Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%)		5,000		4,881		4,881
		4.50% ETP, Due 10/1/18)
LifePrint Group, Inc. (2)	Diagnostics	Term Loan (11.00% cash (Libor + 10.50%; Floor		2,400		2,366		2,366
		11.00%; Ceiling 12.50%), 3.00% ETP, Due 1/1/18)
Watermark Medical, Inc. (2)	Other Healthcare	Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;		3,500		3,494		3,494
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
		Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;		3,500		3,494		3,494
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
		Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;		1,250		1,248		1,248
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
Innovatient Solutions, Inc. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor		1,000		977		977
		11.00%, Ceiling 13.00%); 4.00% ETP, Due 7/1/18)
MedAvante, Inc. (2)	Software	Term Loan (9.75% cash (Libor + 9.25%; Floor		3,000		2,957		2,957
		9.75%), 4.00% ETP, Due 1/1/19)
		Term Loan (9.75% cash (Libor + 9.25%; Floor		3,000		2,957		2,957
		9.75%), 4.00% ETP, Due 1/1/19)
		Term Loan (9.75% cash (Libor + 9.25%; Floor		4,000		3,934		3,934
		9.75%), 4.00% ETP, Due 7/1/19)
Medsphere Systems Corporation (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor		5,000		4,921		4,921
		10.50%), 7.00% ETP, Due 7/1/19)
		Term Loan (10.50% cash (Libor + 10.00%; Floor		2,500		2,461		2,461
		10.50%), 7.00% ETP, Due 7/1/19)
Recondo Technology, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor		1,384		1,380		1,380
		11.50%), 6.60% ETP, Due 12/1/17)
		Term Loan (11.00% cash (Libor + 10.50%; Floor		2,500		2,494		2,494
		11.00%), 4.50% ETP, Due 12/1/17)

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

(Dollars in thousands)

Principal

Cost of

Fair

Portfolio Company (1)

Sector

Type of Investment (3)(4)(7)(9)(10)

Amount

Investments (6)

Value

Term Loan (10.50% cash (Libor + 10.00%; Floor

2,500

2,495

10.50%), 2.75% ETP, Due 12/1/17)

Term Loan (10.50% cash (Libor + 10.00%; Floor

3,000

2,965

10.50%), 2.50% ETP, Due 1/1/19)

Total Debt Investments — Healthcare information and services

43,024

Total Debt Investments

244,899

242,167

Warrant Investments — 4.2% (8)

Warrants — Life Science — 0.8% (8)

ACT Biotech Corporation

Biotechnology

1,521,820 Preferred Stock Warrants

—

Argos Therapeutics, Inc. (2)(5)

Biotechnology

33,112 Common Stock Warrants

—

Celsion Corporation (5)

Biotechnology

5,708 Common Stock Warrants

—

Inotek Pharmaceuticals Corporation (5)

Biotechnology

28,204 Preferred Stock Warrants

149

New Haven Pharmaceuticals, Inc. (2)

Biotechnology

103,982 Preferred Stock Warrants

178

Nivalis Therapeutics, Inc. (5)

Biotechnology

18,534 Common Stock Warrants

122

—

Ocera Therapeutics, Inc. (2)(5)

Biotechnology

6,460 Common Stock Warrants

—

Palatin Technologies, Inc. (2)(5)

Biotechnology

608,058 Common Stock Warrants

Revance Therapeutics, Inc. (5)

Biotechnology

34,377 Common Stock Warrants

684

Sample6, Inc. (2)

Biotechnology

351,018 Preferred Stock Warrants

Sunesis Pharmaceuticals, Inc. (5)

Biotechnology

12,302 Common Stock Warrants

—

AccuVein Inc. (2)

Medical Device

75,769 Preferred Stock Warrants

Direct Flow Medical, Inc.

Medical Device

176,922 Preferred Stock Warrants

144

EnteroMedics, Inc. (5)

Medical Device

141,025 Common Stock Warrants

347

—

IntegenX, Inc. (2)

Medical Device

158,006 Preferred Stock Warrants

Lantos Technologies, Inc. (2)

Medical Device

1,287,817 Preferred Stock Warrants

Mederi Therapeutics, Inc. (2)

Medical Device

248,736 Preferred Stock Warrants

Mitralign, Inc. (2)

Medical Device

641,909 Preferred Stock Warrants

NinePoint Medical, Inc. (2)

Medical Device

566,038 Preferred Stock Warrants

OraMetrix, Inc. (2)

Medical Device

812,348 Preferred Stock Warrants

—

Tryton Medical, Inc. (2)

Medical Device

122,362 Preferred Stock Warrants

ViOptix, Inc.

Medical Device

375,763 Preferred Stock Warrants

—

ZetrOZ, Inc. (2)

Medical Device

475,561 Preferred Stock Warrants

—

Total Warrants — Life Science

1,361

1,331

Warrants — Technology — 2.6% (8)

Ekahau, Inc. (2)

Communications

978,261 Preferred Stock Warrants

OpenPeak, Inc.

Communications

18,997 Common Stock Warrants

—

Overture Networks, Inc.

Communications

385,617 Preferred Stock Warrants

386

Additech, Inc. (2)

Consumer-related Technologies

150,000 Preferred Stock Warrants

Everyday Health, Inc. (5)

Consumer-related Technologies

43,783 Common Stock Warrants

Gwynnie Bee, Inc. (2)

Consumer-related Technologies

268,591 Preferred Stock Warrants

634

If(we), Inc.

Consumer-related Technologies

190,868 Preferred Stock Warrants

Rhapsody International Inc. (2)

Consumer-related Technologies

852,273 Common Stock Warrants

164

165

SavingStar, Inc. (2)

Consumer-related Technologies

79,088 Preferred Stock Warrants

XIOtech, Inc.

Data Storage

2,217,979 Preferred Stock Warrants

SimpleTuition, Inc.

Internet and media

189,573 Preferred Stock Warrants

The NanoSteel Company, Inc. (2)

Materials

147,424 Preferred Stock Warrants

IntelePeer, Inc.

Networking

141,549 Common Stock Warrants

Nanocomp Technologies, Inc. (2)

Networking

272,728 Preferred Stock Warrants

Aquion Energy, Inc.

Power Management

115,051 Preferred Stock Warrants

Powerhouse Dynamics, Inc. (2)

Power Management

290,698 Preferred Stock Warrants

Avalanche Technology, Inc. (2)

Semiconductors

202,602 Preferred Stock Warrants

101

eASIC Corporation (2)

Semiconductors

40,445 Preferred Stock Warrants

InVisage Technologies, Inc. (2)

Semiconductors

185,790 Preferred Stock Warrants

Kaminario, Inc.

Semiconductors

1,087,203 Preferred Stock Warrants

Luxtera, Inc.(2)

Semiconductors

2,304,667 Preferred Stock Warrants

103

Soraa, Inc. (2)

Semiconductors

180,000 Preferred Stock Warrants

102

Xtera Communications, Inc. (5)

Semiconductors

37,831 Preferred Stock Warrants

206

—

Bolt Solutions Inc. (2)

Software

202,892 Preferred Stock Warrants

113

119

Bridge2 Solutions, Inc.

Software

1,769 Common Stock Warrants

688

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

(Dollars in thousands)

			Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Investments (6)		Value
Clarabridge, Inc.	Software	53,486 Preferred Stock Warrants		14		82
Crowdstar, Inc. (2)	Software	75,428 Preferred Stock Warrants		14		14
Decisyon, Inc. (2)	Software	2,526,909 Common Stock Warrants		46		—
Digital Signal Corporation	Software	85,308 Common Stock Warrants		32		32
Education Elements, Inc. (2)	Software	238,122 Preferred Stock Warrants		28		29
Lotame Solutions, Inc. (2)	Software	288,115 Preferred Stock Warrants		22		271
Lytx, Inc.	Software	71,639 Preferred Stock Warrants		20		121
Netuitive, Inc.	Software	41,569 Common Stock Warrants		48		—
Riv Data Corp. (2)	Software	237,361 Preferred Stock Warrants		13		12
ScoreBig, Inc. (2)	Software	481,198 Preferred Stock Warrants		55		57
SIGNiX, Inc. (2)	Software	63,365 Preferred Stock Warrants		48		49
Skyword, Inc.	Software	301,056 Preferred Stock Warrants		48		48
SpringCM, Inc. (2)	Software	2,385,686 Preferred Stock Warrants		55		54
Sys-Tech Solutions, Inc.	Software	375,000 Preferred Stock Warrants		242		524
Vidsys, Inc.	Software	37,346 Preferred Stock Warrants		23		—
Visage Mobile, Inc.	Software	1,692,047 Preferred Stock Warrants		19		—
xTech Holdings, Inc. (2)	Software	111,111 Preferred Stock Warrants		30		32
Total Warrants — Technology				2,316		4,181
Warrants — Cleantech — 0.2% (8)
Renmatix, Inc.	Alternative Energy	53,022 Preferred Stock Warrants		68		68
Semprius, Inc.	Alternative Energy	519,981 Preferred Stock Warrants		25		21
Rypos, Inc. (2)	Energy Efficiency	5,627 Preferred Stock Warrants		44		32
Tigo Energy, Inc. (2)	Energy Efficiency	804,604 Preferred Stock Warrants		100		111
Lehigh Technologies, Inc. (2)	Waste Recycling	272,727 Preferred Stock Warrants		32		34
Total Warrants — Cleantech				269		266
Warrants — Healthcare information and services — 0.6% (8)
Accumetrics, Inc.	Diagnostics	100,928 Preferred Stock Warrants		108		63
BioScale, Inc. (2)	Diagnostics	315,618 Common Stock Warrants		54		—
Candescent Health, Inc. (2)	Diagnostics	519,992 Preferred Stock Warrants		378		—
Helomics Corporation	Diagnostics	13,461Common Stock Warrants		73		—
Interleukin Genetics, Inc. (2)(5)	Diagnostics	2,492,523 Common Stock Warrants		112		2
LifePrint Group, Inc. (2)	Diagnostics	49,000 Preferred Stock Warrants		29		24
Singulex, Inc.	Other Healthcare	293,632 Preferred Stock Warrants		43		167
Verity Solutions Group, Inc.	Other Healthcare	300,360 Preferred Stock Warrants		100		36
Watermark Medical, Inc. (2)	Other Healthcare	27,373 Preferred Stock Warrants		74		65
Innovatient Solutions, Inc. (2)	Software	157,895 Preferred Stock Warrants		35		35
MedAvante, Inc. (2)	Software	114,285 Preferred Stock Warrants		66		68
Medsphere Systems Corporation (2)	Software	7,097,791 Preferred Stock Warrants		60		210
Recondo Technology, Inc. (2)	Software	556,796 Preferred Stock Warrants		95		197
Total Warrants — Healthcare information and services				1,227		867
Total Warrants				5,173		6,645

Other Investments — 0.2% (8)
Vette Technology, LLC	Data Storage	Royalty Agreement Due 4/18/2019		4,422		300
Total Other Investments				4,422		300
Equity — 0.7% (8)
Insmed Incorporated (5)	Biotechnology	33,208 Common Stock		238		603
Revance Therapeutics, Inc.(5)	Biotechnology	4,861 Common Stock		73		166
Sunesis Pharmaceuticals, Inc. (5)	Biotechnology	78,493 Common Stock		83		70
Overture Networks Inc.	Communications	772,382 Common Stock		482		—
SnagAJob.com, Inc.	Consumer-related Technologies	151,655 Common Stock		23		215
Decisyon, Inc.	Technology	2,301,717 Common Stock		101		101
Total Equity				1,000		1,155
Total Portfolio Investment Assets — 156.7% (8)			$	255,494	$	250,267

Short Term Investments — Money Market Funds — 0.2% (8)
US Bank Money Market Deposit Account			$	285	$	285
Total Short Term Investments — Money Market Funds			$	285	$	285

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

(Dollars in thousands)

			Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Investments (6)		Value
Short Term Investments — Restricted Investments— 0.7% (8)
US Bank Money Market Deposit Account (2)			$	1,091	$	1,091
Total Short Term Investments — Restricted Investments			$	1,091	$	1,091

(1)		All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(2)		Has been pledged as collateral under the Key Facility or the 2013-1 Securitization.

(3)		All investments are less than 5% ownership of the class and ownership of the portfolio company.

(4)		All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”) and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the debt investment, unless otherwise indicated. Debt investments based on LIBOR are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of December 31, 2015 is provided.

(5)		Portfolio company is a public company.

(6)		For debt investments, represents principal balance less unearned income.

(7)		Warrants, Equity and Other Investments are non-income producing.

(8)		Value as a percent of net assets.

(9)		The Company did not have any non-qualifying assets under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”), as of December 31, 2015. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10)		ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11)		Debt investment is on non-accrual status at December 31, 2015.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Note 1. Organization

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income and capital gains the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and cleantech industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the NASDAQ Global Select Market under the symbol “HRZN”. The Company was formed to continue and expand the business of Compass Horizon Funding Company LLC, a Delaware limited liability company, which commenced operations in March 2008 and became the Company’s wholly owned subsidiary upon the completion of the Company’s IPO.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

Longview SBIC GP LLC and Longview SBIC LP (collectively, “Horizon SBIC”) were formed as a Delaware limited liability company and Delaware limited partnership, respectively, on February 11, 2011. Horizon SBIC are wholly owned subsidiaries of the Company and were formed in anticipation of obtaining a license to operate a small business investment company from the U. S. Small Business Administration. There has been no activity in Horizon SBIC since its inception.

The Company formed Horizon Funding 2013-1 LLC (“2013-1 LLC”) as a Delaware limited liability company on June 7, 2013 and Horizon Funding Trust 2013-1 (“2013-1 Trust” and, together with 2013-1 LLC, the “2013-1 Entities”) as a Delaware trust on June 18, 2013. The 2013-1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2013-1 Entities for purposes of securitizing $189.3 million of secured loans (the “2013-1 Securitization”) and issuing fixed-rate asset-backed notes in an aggregate principal amount of $90 million (the “Asset-Backed Notes”).

The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy which is a separate legal entity from the Company.

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement, (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”), under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

On March 24, 2015, the Company completed a public offering of 2,000,000 shares of its common stock at a public offering price of $13.95 per share, for total net proceeds to the Company of $26.5 million, after deducting underwriting commission and discounts and other offering expenses.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Note 2. Basis of presentation and significant accounting policies

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10-Q and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2015.

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s subsidiaries in its consolidated financial statements.

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 5. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 5 for additional information regarding fair value.

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and cleantech industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Investments

Investments are recorded at fair value. The Company’s board of directors (the “Board”) determines the fair value of the Company’s portfolio investments. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of March 31, 2016, there was one debt investment on non-accrual status with a cost of $0.9 million and a fair value of $0.3 million. For the three ended March 31, 2015, the Company recognized interest income payments of $0.1 million received from one portfolio company whose debt investment was on non-accrual status. As of December 31, 2015, there was one investment on non-accrual status with a cost of $2.7 million and a fair value of $0.5 million.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended March 31, 2016 and 2015 was 20.5% and 7.4%, respectively.

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are also recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of March 31, 2016 and December 31, 2015 was $1.7 million and $1.9 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of March 31, 2016 and December 31, 2015 were $4.1 million and $3.9 million, respectively. The amortization expense for the three months ended March 31, 2016 and 2015 was $0.2 million and $0.3 million, respectively.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid corporate-level U.S. federal income tax on the income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with Paragraph 946-205-45-3 of the Financial Accounting Standards Board’s (“FASB’s”), Accounting Standards Codification, as amended (“ASC”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the three months ended March 31, 2015, the Company reclassified $1.0 million to paid-in capital from distributions in excess of net investment income of $0.9 million and net realized loss on investments of $0.1 million, which related to excise taxes paid in prior years.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three months ended March 31, 2016, there was no U.S. federal excise tax accrual recorded. For the three months ended March 31, 2015, $0.01 million accrual was recorded for U.S. federal excise tax.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at March 31, 2016 and December 31, 2015. The 2014, 2013 and 2012 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized long-term capital gains, if any, are distributed at least annually, although the Company may decide to retain such capital gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board authorizes, and the Company declares, a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may use newly issued shares to implement the plan (especially if the Company’s shares are trading at a premium to net asset value), or the Company may purchase shares in the open market to fulfill its obligations under the plan.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Stock Repurchase Program

On September 28, 2015, the Board authorized a stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended, and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of September 30, 2016 or the repurchase of $5.0 million of the Company’s common stock. During the three months ended March 31, 2016, the Company did not make any repurchases of its common stock. Since inception, the Company repurchased 113,382 shares of its common stock at an average price of $11.53 on the open market at a total cost of $1.3 million.

Transfers of financial assets

Assets related to transactions that do not meet Accounting Standards Codification Topic 860 — Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets, and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Recently adopted accounting pronouncement

In April 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”) containing guidance that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, instead of being recorded as a separate asset. The Company has adopted ASU 2015-03 which did not have a material impact on the Company’s consolidated financial statements other than corresponding reductions to total assets and total liabilities on the consolidated statements of assets and liabilities. Prior to adoption, the Company recorded debt issuance costs in other assets as an asset on the consolidated statements of assets and liabilities. Upon adoption, the Company reclassified these costs as unamortized debt issuance costs that reduce debt in the liabilities on the consolidated statements of assets and liabilities and retrospectively reclassified the debt issuance costs that were previously presented in other assets as an asset as of December 31, 2015, as discussed further in Note 6.

Note 3. Related party transactions

Investment Management Agreement

The Investment Management Agreement was reapproved by the Board on July 29, 2015. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the U.S. Securities and Exchange Commission. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management fee under the Investment Management Agreement is calculated at an annual rate of 2.00% of (i) the Company’s gross assets, less (ii) assets consisting of cash and cash equivalents, and is payable monthly in arrears. For purposes of calculating the base management fee, the term “gross assets” includes any assets acquired with the proceeds of leverage.

The base management fee payable at March 31, 2016 and December 31, 2015 was $0.4 million. The base management fee expense was $1.3 million and $1.0 million for the three months ended March 31, 2016 and 2015, respectively.

The incentive fee has two parts, as follows:

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with payment-in-kind interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a 1.75% (which is 7.00% annualized) hurdle rate and a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875%. The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Commencing with the calendar quarter beginning July 1, 2014, the incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) commenced on July 1, 2014 and increases by one quarter in length at the end of each calendar quarter until June 30, 2017, after which time, the Incentive Fee Look-back Period will include the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period. As of March 31, 2016 and December 31, 2015, the quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income was not limited by the Incentive Fee Cap and Deferral Mechanism.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The performance based incentive fee expense was $1.1 million and $0.7 million for the three months ended March 31, 2016 and 2015, respectively. The performance based incentive fee payable as of March 31, 2016 and December 31, 2015 was $1.1 million and $1.0 million, respectively. The entire incentive fee payable as of March 31, 2016 and December 31, 2015 represented part one of the incentive fee.

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.3 million for the three months ended March 31, 2016 and 2015.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Note 4. Investments

The following table shows the Company’s investments as of March 31, 2016 and December 31, 2015:

	March 31, 2016				December 31, 2015
	Cost		Fair Value		Cost		Fair Value
			(In thousands)
Money market funds	$	291	$	291	$	285	$	285
Restricted investments in money market funds	$	652	$	652	$	1,091	$	1,091
Non-affiliate investments
Debt	$	240,792	$	238,426	$	244,899	$	242,167
Warrants		5,153		5,132		5,173		6,645
Other		4,782		700		4,422		300
Equity		549		777		1,000		1,155
Total non-affiliate investments	$	251,276	$	245,035	$	255,494	$	250,267

The following table shows the Company’s non-affiliate investments by industry sector as of March 31, 2016 and December 31, 2015:

	March 31, 2016				December 31, 2015
	Cost		Fair Value		Cost		Fair Value
			(In thousands)
Life Science
Biotechnology	$	35,602	$	35,611	$	36,932	$	37,911
Medical Device		22,431		21,842		25,753		22,736
Technology
Communications		12,310		12,207		20,170		19,916
Consumer-Related		20,152		20,739		18,699		19,421
Data Storage		4,421		318		4,444		319
Internet and Media		63		65		63		69
Materials		9,931		9,928		9,918		9,920
Networking		3,641		3,623		757		740
Power Management		2,494		2,547		2,490		2,541
Semiconductors		16,874		16,569		18,944		18,628
Software		69,268		68,573		60,792		61,897
Cleantech
Alternative Energy		1,695		1,686		2,942		2,938
Energy Efficiency		3,258		3,254		3,371		3,370
Waste Recycling		5,972		5,973		5,968		5,970
Healthcare Information and Services
Diagnostics		7,715		7,098		8,001		7,336
Other		8,454		8,499		8,453		8,504
Software		26,995		26,503		27,797		28,051
Total non-affiliate investments	$	251,276	$	245,035	$	255,494	$	250,267

Note 5. Fair value

The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1

Quoted prices in active markets for identical assets and liabilities.

Level 2

Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Investments are valued at fair value as determined in good faith by the Board, based on input of management, the audit committee and independent valuation firms which are engaged at the direction of the Board to assist in the valuation of each portfolio investment lacking a readily available market quotation at least once during a trailing twelve-month period under a valuation policy and a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

Because there is not a readily available market value for most of the investments in its portfolio, the Company values substantially all of its portfolio investments at fair value as determined in good faith by the Board, as described herein. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Additionally, the fair value of the Company's investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: For variable rate debt investments which re-price frequently and have no significant change in credit risk, carrying values are a reasonable estimate of fair values. The fair value of fixed rate debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. At March 31, 2016 and December 31, 2015, the hypothetical market yield used ranged from 11% to 25%. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

•

Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

•

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

•

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

•

Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment.

•

Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or IPOs, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying agreement. The Company currently values one contractual agreement using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized this other investment as Level 3 within the fair value hierarchy described above. This asset is recorded at fair value on a recurring basis.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of its investments as of March 31, 2016 and December 31, 2015. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of March 31, 2016:

March 31, 2016
	Fair		Valuation Techniques/	Unobservable				Weighted
Investment Type	Value		Methodologies	Input	Range			Average
(Dollars in thousands, except per share data)
Debt investments	$	238,176	Discounted Expected Future Cash Flows	Hypothetical Market Yield		11% – 25	%		13	%

		250	Liquidation Scenario	Discount Rate		18	%		18	%
				Probability Weighting		50	%		50	%

Warrant investments		4,897	Black-Scholes Valuation Model	Price Per Share		$0.00 – $63.98		$	3.80
				Average Industry Volatility		18	%		18	%
				Marketability Discount		20	%		20	%
				Estimated Time to Exit		1 to 5 years			3 years

Other investments		700	Multiple Probability Weighted	Discount Rate		25	%		25	%
			Cash Flow Model	Probability Weighting		0% – 100	%		33	%

Equity investments		229	Last Equity Financing	Price Per Share		$0. 04 – $1.00		$	0.39
Total Level 3 investments	$	244,252

December 31, 2015
	Fair		Valuation Techniques/	Unobservable				Weighted
Investment Type	Value		Methodologies	Input	Range			Average
(Dollars in thousands, except per share data)
Debt investments	$	241,667	Discounted Expected Future Cash Flows	Hypothetical Market Yield		11% – 25	%		13	%

		500	Liquidation Scenario	Discount Rate		25	%		25	%
				Probability Weighting		0% – 100	%		30	%

Warrant investments		5,407	Black-Scholes Valuation Model	Price Per Share		$0.00 – $615.46		$	81.27
				Average Industry Volatility Volatility		18	%		18	%
				Marketability Discount		20	%		20	%
				Estimated Time to Exit		1 to 5 years			3 years

		386	Expected Acquisition Settlement	Price Per Share	$	2.09		$	2.09

Other investments		300	Multiple Probability Weighted	Discount Rate		25	%		25	%
			Cash Flow Model	Probability Weighting		100	%		100	%

Equity investments		101	Last Equity Financing	Price Per Share	$	0.04		$	0.04

		215	Expected Settlement	Price Per Share		$0.00 – $1.41		$	1.41
Total Level 3 investments	$	248,576

Borrowings: The carrying amount of borrowings under the Company’s revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”) approximates fair value due to the variable interest rate of the Key Facility and is categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed rate 2019 Notes (as defined in Note 6) is based on the closing public share price on the date of measurement. On March 31, 2016, the closing price of the 2019 Notes on the New York Stock Exchange was $25.40 per note, or $33.5 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on March 31, 2016, the Asset-Backed Notes (as defined in Note 6) were trading at par value, or $8.7 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	March 31, 2016
	Total		Level 1		Level 2		Level 3
	(In thousands)
Money market funds	$	291	$	—	$	291	$	—
Restricted investments in money market funds	$	652	$	—	$	652	$	—
Debt investments	$	238,426	$	—	$	—	$	238,426
Warrant investments	$	5,132	$	—	$	235	$	4,897
Other investments	$	700	$	—	$	—	$	700
Equity investments	$	777	$	548	$	—	$	229

	December 31, 2015
	Total		Level 1		Level 2		Level 3
	(In thousands)
Money market funds	$	285	$	—	$	285	$	—
Restricted investments in money market funds	$	1,901	$	—	$	1,901	$	—
Debt investments	$	242,167	$	—	$	—	$	242,167
Warrant investments	$	6,645	$	—	$	852	$	5,793
Other investments	$	300	$	—	$	—	$	300
Equity investments	$	1,155	$	839	$	—	$	316

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended March 31, 2016:

	Three Months Ended March 31, 2016
	Debt Investments			Warrant Investments			Equity Investments			Other Investments			Total
	(In thousands)
Level 3 assets, beginning of period	$	242,167		$	5,793		$	316		$	300		$	248,576
Purchase of investments		16,500			—			—			—			16,500
Warrants and equity received and classified as Level 3		—			81			45			—			126
Principal payments received on investments		(18,060	)		—			—			(23	)		(18,083	)
Proceeds from sale of investments		—			(709	)		(127	)		—			(836	)
Net realized (loss) gain on investments		(2,157	)		608			(369	)		—			(1,918	)
Unrealized appreciation (depreciation) included in earnings		366			(876	)		364			40			(106	)
Transfer from debt investments to other investments		(383	)		—			—			383			—
Other		(7	)		—			—			—			(7	)
Level 3 assets, end of period	$	238,426		$	4,897		$	229		$	700		$	244,252

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

The Company’s transfers between levels are recognized at the end of each reporting period. During the three months ended March 31, 2016, there were no transfers between levels.

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at March 31, 2016 includes $1.8 million in unrealized depreciation on debt and other investments, $0.5 million in unrealized depreciation on warrant investments and $0.1 million in unrealized appreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended March 31, 2015:

	Three Months Ended March 31, 2015
	Debt Investments			Warrant Investments			Equity Investments		Other Investments			Total
	(In thousands)
Level 3 assets, beginning of period	$	199,180		$	3,966		$	222	$	300		$	203,668
Purchase of investments		23,933			—			—		—			23,933
Warrants and equity received and classified as Level 3		—			151			—		—			151
Principal payments received on investments		(25,720	)		—			—		(70	)		(25,790	)
Net realized loss on investments		—			(230	)		—		—			(230	)
Unrealized appreciation included in earnings		219			392			—		70			681
Transfer out of Level 3		—			(15	)		—		—			(15	)
Other		(2	)		—			—		—			(2	)
Level 3 assets, end of period	$	197,610		$	4,264		$	222	$	300		$	202,396

The Company’s transfers between levels are recognized at the end of the applicable reporting period. During the three months ended March 31, 2015, there were no transfers between Level 1 and Level 2. The transfer out of Level 3 relates to warrants held in one portfolio company, with an aggregate fair value of $0.02 million, that was transferred into Level 2 upon the portfolio company becoming a public company during the period.

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at March 31, 2015 includes $0.2 million in unrealized appreciation on debt investments and $0.2 million in unrealized appreciation on warrants.

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts for 2016 and 2015 have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of March 31, 2016 and December 31, 2015, the recorded balances equaled fair values of all the Company’s financial instruments, except for the Company’s 2019 Notes, as previously described.

Off-balance-sheet instruments

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Note 6. Borrowings

The following table shows the Company’s borrowings as of March 31, 2016 and December 31, 2015:

	March 31, 2016							December 31, 2015
	Total Commitment		Balance Outstanding			Unused Commitment		Total Commitment		Balance Outstanding			Unused Commitment
						(In thousands)
Asset-Backed Notes	$	8,696	$	8,696		$	—	$	14,546	$	14,546		$	—
Key Facility		70,000		68,000			2,000		70,000		68,000			2,000
2019 Notes		33,000		33,000			—		33,000		33,000			—
Total before debt issuance costs		111,696		109,696			2,000		117,546		115,546			2,000
Unamortized debt issuance costs attributable to term borrowings		—		(545	)		—		—		(592	)		—
Total borrowings outstanding, net	$	111,696	$	109,151		$	2,000	$	117,546	$	114,954		$	2,000

In accordance with the 1940 Act, with certain limited exceptions, the Company is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 200% after such borrowings. As of March 31, 2016, the asset coverage for borrowed amounts was 244%.

On August 12, 2015, the Company amended the Key Facility to (1) add a $20 million commitment to the existing $50 million commitment and (2) extend the term of the Key Facility. The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the current $70 million commitment. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 50% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Key Facility has a three-year revolving period followed by a two-year amortization period and matures on August 12, 2020. The interest rate is based upon the one-month London Interbank Offered Rate (“LIBOR”), plus a spread of 3.25%, with a LIBOR floor of 0.75%. Based on a LIBOR rate of 0.44% and 0.43% on March 31, 2016 and December 31, 2015, respectively, the interest rate was 4.00% as of March 31, 2016 and December 31, 2015. The average rate for the three months ended March 31, 2016 and 2015 was 4.00%. As of March 31, 2016 and December 31, 2015, the Company had available borrowing capacity of $2.0 million, subject to existing terms and advance rates.

On March 23, 2012, the Company issued and sold an aggregate principal amount of $30 million of 7.375% senior unsecured notes due in 2019 and on April 18, 2012, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $3 million of such notes (collectively, the “2019 Notes”). The 2019 Notes will mature on March 15, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time at a redemption price of $25 per security plus accrued and unpaid interest. The 2019 Notes bear interest at a rate of 7.375% per year payable quarterly on March 15, June 15, September 15 and December 15 of each year. The 2019 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2019 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of March 31, 2016, the Company was in material compliance with the terms of the 2019 Notes. The 2019 Notes are listed on the New York Stock Exchange under the symbol “HTF”.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

On June 28, 2013, the Company completed the 2013-1 Securitization. In connection with the 2013-1 Securitization, 2013-1 Trust, a wholly owned subsidiary of the Company, issued $90 million in the Asset-Backed Notes, which are rated A1(sf) by Moody’s Investors Service, Inc. The Company is the sponsor, originator and servicer for the transaction. The Asset-Backed Notes bear interest at a fixed rate of 3.00% per annum and have a stated maturity of May 15, 2018. As of March 31, 2016, 13.9%, or $33.2 million, of the Company’s total debt investment portfolio at fair value was held through the 2013-1 Securitization.

The Asset-Backed Notes were issued by 2013-1 Trust pursuant to a note purchase agreement (the “Note Purchase Agreement”), dated as of June 28, 2013, by and among the Company, 2013-1 LLC, as trust depositor, 2013-1 Trust and Guggenheim Securities, LLC (“Guggenheim Securities”), as initial purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company (the “Trust Loans”) and secured by certain assets of such portfolio companies. The Trust Loans are serviced by the Company. In connection with the issuance and sale of the Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the Note Purchase Agreement. The Asset-Backed Notes are secured obligations of 2013-1 Trust and are non-recourse to the Company.

As part of the transaction, the Company entered into a sale and contribution agreement, dated as of June 28, 2013 (the “Sale and Contribution Agreement”), with 2013-1 LLC, pursuant to which the Company sold or contributed to 2013-1 LLC the Trust Loans. The Company made customary representations, warranties and covenants in the Sale and Contribution Agreement with respect to the Trust Loans as of the date of the transfer of the Trust Loans to 2013-1 LLC. The Company also entered into a sale and servicing agreement, dated as of June 28, 2013 (the “Sale and Servicing Agreement”), with 2013-1 LLC and 2013-1 Trust pursuant to which 2013-1 LLC sold or contributed the Trust Loans to 2013-1 Trust. The Company has made customary representations, warranties and covenants in the Sale and Servicing Agreement. The Company serves as administrator to 2013-1 Trust pursuant to an administration agreement, dated as of June 28, 2013, with 2013-1 Trust, Wilmington Trust, National Association, and U.S. Bank National Association. 2013-1 Trust also entered into an indenture, dated as of June 28, 2013, which governs the Asset-Backed Notes and includes customary covenants and events of default. In addition, 2013-1 LLC entered into an amended and restated trust agreement, dated as of June 28, 2013, which includes customary representations, warranties and covenants. The Asset-Backed Notes were sold through an unregistered private placement to “qualified institutional buyers” in compliance with the exemption from registration provided by Rule 144A under the Securities Act, and to institutional “accredited investors” (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) who, in each case, were “qualified purchasers” for purposes of Section 3(c)(7) under the 1940 Act.

Under the terms of the Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through principal collections from the underlying securitized debt portfolio, which may be used to make monthly interest and principal payments on the Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds on the consolidated statements of assets and liabilities. The balances of restricted investments in money market funds were $0.7 million and $1.1 million as of March 31, 2016 and December 31, 2015, respectively.

Note 7. Financial instruments with off-balance-sheet risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $2.5 million and $10.0 million as of March 31, 2016 and December 31, 2015, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, such as revolving credit arrangements or similar transactions. These commitments are often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

The following table provides the Company’s unfunded commitments by portfolio company as of March 31, 2016:

	Principal Balance		Fair Value of Unfunded Commitment Liability
	(In thousands)
Lehigh Technologies, Inc.	$	1,500	$	14
ScoreBig, Inc.		1,000		—
Total	$	2,500	$	14

The table above also provides the fair value of the Company’s unfunded commitment liability as of March 31, 2016 totaling $0.01 million. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

Note 8. Concentrations of credit risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and cleantech industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments represented 21% of total debt investments outstanding as of March 31, 2016 and December 31, 2015. No single debt investment represented more than 10% of the total debt investments as of March 31, 2016 and December 31, 2015. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments accounted for 20% and 24% of total interest and fee income on investments for the three months ended March 31, 2016 and 2015, respectively.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

Note 9. Distributions

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the three months ended March 31, 2016 and for the years ended December 31, 2015 and 2014:

Date Declared	Record Date	Payment Date	Amount Per Share		Cash Distribution		DRIP Shares Issued		DRIP Share Value
			(In thousands, except share and per share data)
Three Months Ended March 31, 2016
3/3/16	5/19/16	6/15/16	$	0.115	$	—		—	$	—
3/3/16	4/20/16	5/16/16		0.115		—		—		—
3/3/16	3/18/16	4/15/16		0.115		1,306		1,840		21
			$	0.345	$	1,306		1,840	$	21
Year Ended December 31, 2015
10/30/15	2/22/16	3/15/16	$	0.115	$	1,309		1,606	$	18
10/30/15	1/21/16	2/17/16		0.115		1,308		1,931		18
10/30/15	12/18/15	1/15/16		0.115		1,311		1,841		18
7/29/15	11/19/15	12/15/15		0.115		1,317		1,687		20
7/29/15	10/20/15	11/16/15		0.115		1,317		1,967		22
7/29/15	9/18/15	10/15/15		0.115		1,315		2,418		24
5/1/15	8/19/15	9/15/15		0.115		1,312		2,577		26
5/1/15	7/20/15	8/14/15		0.115		1,312		2,420		27
5/1/15	6/18/15	7/15/15		0.115		1,312		2,045		26
3/6/15	5/20/15	6/15/15		0.115		1,311		2,036		28
3/6/15	4/20/15	5/15/15		0.115		1,311		1,950		28
3/6/15	3/20/15	4/15/15		0.115		1,095		877		12
			$	1.380	$	15,530		23,355	$	267
Year Ended December 31, 2014
10/31/14	2/19/15	3/16/15	$	0.115	$	1,096		751	$	11
10/31/14	1/20/15	2/13/15		0.115		1,094		956		12
10/31/14	12/17/14	1/15/15		0.115		1,096		786		11
8/1/14	11/19/14	12/15/14		0.115		1,093		1,099		15
8/1/14	10/20/14	11/17/14		0.115		1,095		850		12
8/1/14	9/18/14	10/15/14		0.115		1,095		901